ArticleBioengineering (Basel, Switzerland)2024
Joint Screening for Ultra-High Dimensional Multi-Omics Data.
Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Investigators often face ultra-high dimensional multi-omics data, where identifying significant genes and omics within a gene is of interest. In such data, each gene forms a group consisting of its multiple omics. Moreover, some genes may also be highly correlated. This leads to a tri-level hierarchical structured data: the cluster level, which is the group of correlated genes, the subgroup level, which is the group of omics of the same gene, and the individual level, which consists of omics. Screening is widely used to remove unimportant variables so that the number of remaining variables becomes smaller than the sample size. Penalized regression with the remaining variables after performing screening is then used to identify important variables. To screen unimportant genes, we propose to cluster genes and conduct screening. We show that the proposed screening method possesses the sure screening property. Extensive simulations show that the proposed screening method outperforms competing methods. We apply the proposed variable selection method to the TCGA breast cancer dataset to identify genes and omics that are related to breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.